Related Experiment Video

Updated: Feb 13, 2026

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models
13:43

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models

Published on: April 1, 2022

5.0K

Lapatinib nano-delivery systems: a promising future for breast cancer treatment

Gunjan Vasant Bonde1, Sarita Kumari Yadav1,2, Sheetal Chauhan3

  • 1a Department of Pharmaceutical Engineering & Technology , Indian Institute of Technology, Banaras Hindu University , Varanasi , India.

Expert Opinion on Drug Delivery
|March 10, 2018
PubMed
Abstract

Insights

New delivery systems enhance Lapatinib (LAPA) for breast cancer treatment. These strategies improve solubility and bioavailability, overcoming limitations of the oral tablet for better patient outcomes.

Area of Science:

  • Pharmacology and Drug Delivery
  • Oncology
  • Biochemistry

Background:

  • Breast cancer is a leading cause of death in women.
  • Lapatinib (LAPA) is a tyrosine kinase inhibitor used for breast cancer.
  • LAPA's clinical use is limited by poor solubility, bioavailability, and high albumin binding.

Purpose of the Study:

  • To review challenges and solutions for LAPA delivery systems.
  • To explore novel LAPA formulations for improved therapeutic efficacy.
  • To cover LAPA-conjugates for diagnostic applications.

Main Methods:

  • Comprehensive literature review of electronic databases.
  • Survey of various LAPA delivery systems (nanoparticles, liposomes, etc.).
  • Discussion of LAPA-conjugate synthesis for diagnostics.

Main Results:

  • Explored delivery systems offer controlled release, enhanced solubility, and bioavailability.
  • Strategies reduce LAPA's dose, toxicity, and plasma protein binding.
  • Novel formulations show potential for maximized clinical efficacy compared to oral tablets.

Conclusions:

  • Alternative non-oral delivery systems are crucial for LAPA.
  • Multiparticulate or nano-delivery systems are needed for targeted administration.
  • Further research into LAPA combinations and clinical trials is recommended.
Keywords:
Active targetingcapecitabineletrozolenano-delivery systempassive targetingtyrosine kinase

More Related Videos

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

19.0K
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

7.1K

Related Concept Videos

Transdermal Drug Delivery Systems01:18

Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
4
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
4
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
3
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
2
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
2
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
3